- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03889379
Albuterol and Immune Cell Composition
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Neuroblastoma is a cancer that typically affects the nerves of children. Sometimes the treatment required for neuroblastoma is an autologous stem cell transplant, where patients who are experiencing neuroblastoma will undergo an expansion of their blood system and collect their peripheral blood to later infuse back into them after chemotherapy and/or radiation. However, up to 14% of individuals experience complications with this procedure.
Research has shown that certain drugs that cause similar effects on the body to that of acute exercise can elicit a more favorable donation. However, these drugs are very costly. Albuterol, on the other hand, is a regularly used drug that may have a similar effect on the body as adrenaline and is used to treat individuals who are experiencing respiratory airway distress. The benefit of albuterol is that it can be administered through inhalation, further reducing patient burden.
The aim of this pilot study is to determine the effects of albuterol on the composition of immune cells in the bloodstream. Five healthy volunteers (age 21-44 years) will be recruited to participate in this study. Each participant will donate a 6ml blood sample before and during a 20-minute continuous albuterol nebulization through an IV catheter. During the last 10 minutes of the nebulization, participants will submit to another 6mL blood draw.
Tipo di studio
Fase
- Prima fase 1
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85724
- University of Arizona Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Any gender
- 21-44 years of age
Exclusion Criteria:
- Subjects must not: be younger than 21 or older than 44 years of age
- Indicate a condition on the ACSM-AHA preexercise screening questionnaire indicating that physician approval is required prior to exercise
- current user of tobacco products or have quit within the previous 6-months
- body mass index of >30 kg/m2, or waist girth of >102cm for men and >88cm for women
- use over-the-counter medication known to affect the immune system (i.e. regular use of ibuprofen/aspirin, anti-histamines or beta-blockers)
- have chronic/debilitating arthritis
- have been bedridden in the past three months
- have common illness (i.e. colds) within the past 6-weeks
- have HIV
- have hepatitis
- have had a stroke
- have major affective disorder
- have any autoimmune disease
- have central or peripheral nervous disorders
- have blood vessel disease
- have cardiovascular disease (CVD)
- use of any prescription medication
- pregnancy or are breast-feeding
- asthma, emphysema, bronchitis, kidney disease; pheochromocytoma; diabetes; overactive thyroid
- history of severe anaphylactic reaction to an allergen
- or are scheduled to have surgery
- Individuals who pass the exclusion criteria detailed above but present with more than one of the following CVD risk factors will also be excluded from the study: family history of myocardial infarction, coronary revascularization, or sudden death before 55 years of age in father or other male first-degree relative or before 65 years of age in mother or other female first-degree relative; hypertension (systolic blood pressure of >140 mmHg or diastolic blood pressure >90 mmHg); dyslipidemia (total serum cholesterol of >200 mg/dl); pre-diabetes (fasting blood glucose of >100mg/dl but <126 mg/dl).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Effects of Albuterol on Immune Cell Composition
This is a single subject repeated measure experimental design with each participant acting as his/her own control.
|
Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Quantification of NK Cells (CD3-/CD56+).
Lasso di tempo: One year
|
Investigators will collect a 6mL blood sample into EDTA anti-coagulant tubes before and during the last five minutes of an albuterol nebulization to assess the quantification in both absolute number and proportion of NK cells (CD3-/CD56+) using a MACSQuant flow cytometer and subsequent analysis on FlowLogic Software (v7.2.1).
The last five minutes of nebulization of blood sample will be directly compared to the pre nebulization blood sample in the same participants in the same research arm.
|
One year
|
|
Quantification of Gamma Delta T Cells (CD4-CD8-).
Lasso di tempo: One year
|
Investigators will collect a 6mL blood sample into EDTA anti-coagulant tubes before and during the last five minutes of an albuterol nebulization to assess the quantification in both absolute number and proportion of Gamma Delta T cells (CD3+/CD4-/CD8-) using a MACSQuant flow cytometer and subsequent analysis on FlowLogic Software (v7.2.1).
The last five minutes of nebulization of blood sample will be directly compared to the pre nebulization blood sample in the same participants in the same research arm.
|
One year
|
|
Quantification of Gamma T cell subsets (CD3+/CD4/CD8).
Lasso di tempo: One year
|
Investigators will collect a 6mL blood sample into EDTA anti-coagulant tubes before and during the last five minutes of an albuterol nebulization to assess the quantification in both absolute number and proportion of T-cell subsets (CD3+/CD4/CD8) using a MACSQuant flow cytometer and subsequent analysis on FlowLogic Software (v7.2.1).
The last five minutes of nebulization of blood sample will be directly compared to the pre nebulization blood sample in the same participants in the same research arm.
|
One year
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Grace M Niemiro, PhD, University of Arizona
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Effetti fisiologici delle droghe
- Agenti adrenergici
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Agenti autonomi
- Agenti del sistema nervoso periferico
- Agonisti adrenergici
- Agenti broncodilatatori
- Agenti antiasmatici
- Agenti del sistema respiratorio
- Agenti di controllo riproduttivo
- Agonisti del recettore adrenergico beta-2
- Beta-agonisti adrenergici
- Agenti tocolitici
- Albuterolo
Altri numeri di identificazione dello studio
- 181229451
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .